SGLT2 inhibitors may reduce systemic autoimmune rheumatic disease risk by 50% in diabetes

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl peptidase 4 inhibitors, according to data.Meanwhile, neither glucagon-like peptide-1 (GLP-1) receptor agonists nor SGLT2 inhibitors bested DPP4 inhibitors for reducing other autoimmune rheumatic